{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/analgesia-mild-to-moderate-pain/","result":{"data":{"firstChapter":{"id":"5ad4aa62-330c-58ef-be3d-541eb0757bd1","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 1439681c-9fa6-49b5-98b8-d5b082d1af2d --><h1>Analgesia - mild-to-moderate pain: Summary</h1><!-- end field 1439681c-9fa6-49b5-98b8-d5b082d1af2d -->","htmlStringContent":"<!-- begin item 301d5456-06df-4ae2-ae5e-87f8280ff075 --><!-- begin field 913e5281-bb97-4ffc-a5b8-a11fcd851666 --><ul><li>An analgesic is a drug used to relieve pain.</li><li>The analgesics used to relieve mild-to-moderate pain are:<ul><li>Paracetamol.</li><li>Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen.</li><li>Aspirin (a salicylate NSAID).</li><li>Weak opioids, such as codeine, dihydrocodeine, and tramadol.</li></ul></li><li>Fixed-dose combination preparations are also available, including:<ul><li>Paracetamol with codeine.</li><li>Paracetamol with dihydrocodeine.</li><li>Paracetamol with tramadol.</li><li>Aspirin with codeine.</li></ul></li><li>For children under 16 years of age, paracetamol or ibuprofen alone is a suitable first-line choice.<ul><li>If the child does not respond to the first-line analgesic, check their adherence and that an appropriate dose is being taken. </li><li>If adherence and dose are appropriate, switch analgesic: if paracetamol has been used, ibuprofen should be tried. If ibuprofen has been used, paracetamol should be tried.</li><li>If the child has not responded sufficiently to the appropriate dose of one drug alone, alternating paracetamol and ibuprofen should be considered.</li><li>If the child is still in pain or more than short courses of analgesics are required, specialist advice should be sought.</li></ul></li><li>For adults and children aged over 16 years, a stepwise strategy for managing mild-to-moderate pain is recommended:<ul><li>Step 1 — paracetamol should be used. </li><li>Step 2 — paracetamol should be substituted with ibuprofen or, if ibuprofen is unsuitable, a weak opioid (such as codeine).</li><li>Step 3 — paracetamol should be added to ibuprofen or the weak opioid.</li><li>Step 4 — paracetamol should be continued and ibuprofen replaced with an alternative NSAID.</li><li>Step 5 — a weak opioid should be started in addition to paracetamol and/or a NSAID.</li></ul></li><li>When prescribing analgesics:<ul><li>A full therapeutic dose of one drug should be used before considering switching to a different analgesic or adding another analgesic.</li><li>The underlying cause of the pain should be treated whenever possible.</li><li>People who experience continuous pain should receive regular analgesia following a full clinical assessment.</li><li>Combination analgesics should be avoided as first-line treatment. Prescribing single constituent analgesics allows independent titration of each drug.</li></ul></li></ul><!-- end field 913e5281-bb97-4ffc-a5b8-a11fcd851666 --><!-- end item 301d5456-06df-4ae2-ae5e-87f8280ff075 -->","topic":{"id":"bb91de96-92a3-5109-9e63-bfa14430451f","topicId":"c277ec09-8e05-40f0-800e-256a40ea6318","topicName":"Analgesia - mild-to-moderate pain","slug":"analgesia-mild-to-moderate-pain","aliases":[],"chapters":[{"id":"5ad4aa62-330c-58ef-be3d-541eb0757bd1","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"f5da487f-1d70-5390-8b2c-eb8ac55dcca3","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"799ae015-7ff2-5d0f-adc6-2b88d19ac732","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"d1128e99-9465-5c81-aa62-b5dfbd77231a","slug":"changes","fullItemName":"Changes"},{"id":"74a19ac7-0b43-56ee-9957-80e1aee10f72","slug":"update","fullItemName":"Update"}]},{"id":"2ec6ad9e-fe4e-5338-be0a-025956dceeda","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"b5e613c3-899b-5b4e-8648-ff702aef6111","slug":"goals","fullItemName":"Goals"},{"id":"8fb7a002-3c19-5ab7-9ddf-8376dd8f563b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"12cf7805-8394-59b8-9dc6-25f55b2baece","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6816edfb-26c1-526d-8e15-0e9c45a99339","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"19cfc3fb-520c-5889-9816-9a767e365a43","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"85fbc6d5-aea7-52dd-8e2b-7792809cf582","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"75f84317-2f35-533b-a07b-8de3c3e62947","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"0728ca52-ba22-539a-b403-09fa11cd8022","slug":"definition","fullItemName":"Definition"},{"id":"732f85cd-41d9-5528-96c3-6f242e3f8736","slug":"types-of-analgesics","fullItemName":"Types of analgesics"},{"id":"4cc4aec7-c1bc-587e-8e30-2bd567709a43","slug":"mode-of-action","fullItemName":"Mode of action"}]},{"id":"3072fb03-9470-5fa4-a035-2669e98df9d8","slug":"management","fullItemName":"Management","subChapters":[{"id":"2d9072b9-4eca-5f7a-9016-80d79ab0bd7d","slug":"choice-of-analgesic","fullItemName":"Scenario: Choice of analgesic"},{"id":"7088bd75-8950-5c20-845e-a5d6297eed85","slug":"paracetamol","fullItemName":"Scenario: Paracetamol"},{"id":"b32885df-ba75-5a6e-9fd1-cb1b6c9ee730","slug":"nsaids","fullItemName":"Scenario: NSAIDs"},{"id":"4e42679f-766d-53a7-bf28-4ec3703913a8","slug":"aspirin","fullItemName":"Scenario: Aspirin"},{"id":"cde4894f-b757-565e-ba2c-44513235cd40","slug":"weak-opioids","fullItemName":"Scenario: Weak opioids"}]},{"id":"d9fe8003-4836-534b-a8e5-d706bd32213c","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"dcff9956-cb3d-54cf-b249-d2c1cdaa2596","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"bce5b7d5-7da6-573e-b8a8-fddc2c7e96b6","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a15bfc66-55aa-561e-ae5e-8fea7ee56982","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"13a5c6cf-ff3c-5c3d-98fd-5f14e4ee6e2a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"66abd73d-e881-52a3-8a3a-46e9f9dea2ff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"73f91468-8f42-546a-86e1-078847155ad0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a93d2597-ba76-5709-9989-de6b10c60c42","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"bb91de96-92a3-5109-9e63-bfa14430451f","topicId":"c277ec09-8e05-40f0-800e-256a40ea6318","topicName":"Analgesia - mild-to-moderate pain","slug":"analgesia-mild-to-moderate-pain","aliases":[],"topicSummary":"For adults, a stepwise strategy for managing mild-to-moderate pain is recommended","lastRevised":"Last revised in August 2020","nextPlannedReviewBy":"2025-08-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2025-07","nextPlannedReviewByDisplay":"July 2025","specialities":[{"id":"45db1917-4d65-58d8-af3d-568321e486ed","name":"Drugs and devices","slug":"drugs-devices"},{"id":"e174a859-759f-5b1d-898e-1a4155645e13","name":"Infections and infestations","slug":"infections-infestations"},{"id":"86ae217e-d675-5678-91c5-7bfbaa88c2f1","name":"Injuries","slug":"injuries"},{"id":"f8332083-731e-50fe-a895-030315ce6083","name":"Musculoskeletal","slug":"musculoskeletal"}],"chapters":[{"id":"5ad4aa62-330c-58ef-be3d-541eb0757bd1","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"f5da487f-1d70-5390-8b2c-eb8ac55dcca3","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"799ae015-7ff2-5d0f-adc6-2b88d19ac732","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"d1128e99-9465-5c81-aa62-b5dfbd77231a","slug":"changes","fullItemName":"Changes"},{"id":"74a19ac7-0b43-56ee-9957-80e1aee10f72","slug":"update","fullItemName":"Update"}]},{"id":"2ec6ad9e-fe4e-5338-be0a-025956dceeda","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"b5e613c3-899b-5b4e-8648-ff702aef6111","slug":"goals","fullItemName":"Goals"},{"id":"8fb7a002-3c19-5ab7-9ddf-8376dd8f563b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"12cf7805-8394-59b8-9dc6-25f55b2baece","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6816edfb-26c1-526d-8e15-0e9c45a99339","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"19cfc3fb-520c-5889-9816-9a767e365a43","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"85fbc6d5-aea7-52dd-8e2b-7792809cf582","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"75f84317-2f35-533b-a07b-8de3c3e62947","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"0728ca52-ba22-539a-b403-09fa11cd8022","slug":"definition","fullItemName":"Definition"},{"id":"732f85cd-41d9-5528-96c3-6f242e3f8736","slug":"types-of-analgesics","fullItemName":"Types of analgesics"},{"id":"4cc4aec7-c1bc-587e-8e30-2bd567709a43","slug":"mode-of-action","fullItemName":"Mode of action"}]},{"id":"3072fb03-9470-5fa4-a035-2669e98df9d8","slug":"management","fullItemName":"Management","subChapters":[{"id":"2d9072b9-4eca-5f7a-9016-80d79ab0bd7d","slug":"choice-of-analgesic","fullItemName":"Scenario: Choice of analgesic"},{"id":"7088bd75-8950-5c20-845e-a5d6297eed85","slug":"paracetamol","fullItemName":"Scenario: Paracetamol"},{"id":"b32885df-ba75-5a6e-9fd1-cb1b6c9ee730","slug":"nsaids","fullItemName":"Scenario: NSAIDs"},{"id":"4e42679f-766d-53a7-bf28-4ec3703913a8","slug":"aspirin","fullItemName":"Scenario: Aspirin"},{"id":"cde4894f-b757-565e-ba2c-44513235cd40","slug":"weak-opioids","fullItemName":"Scenario: Weak opioids"}]},{"id":"d9fe8003-4836-534b-a8e5-d706bd32213c","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"dcff9956-cb3d-54cf-b249-d2c1cdaa2596","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"bce5b7d5-7da6-573e-b8a8-fddc2c7e96b6","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a15bfc66-55aa-561e-ae5e-8fea7ee56982","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"13a5c6cf-ff3c-5c3d-98fd-5f14e4ee6e2a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"66abd73d-e881-52a3-8a3a-46e9f9dea2ff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"73f91468-8f42-546a-86e1-078847155ad0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a93d2597-ba76-5709-9989-de6b10c60c42","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"bb91de96-92a3-5109-9e63-bfa14430451f"}},"staticQueryHashes":["3666801979"]}